CSF3 and Miyoshi myopathy: Our research underscores that for MM patients earmarked for ASCT, incorporating on-demand PXF with HD-Cy and PEG G-CSF not only ensures a robust stem cell yield but is also a cost-effective and safe mobilization approach.